India may soon witness a drastic shift in the affordability of weight loss solutions as the patent for semaglutide, an active ingredient in popular weight-loss drugs like Wegovy and Ozempic, expires this week. This anticipates a surge of generics by domestic pharmaceutical companies, thereby reducing prices and increasing access for a population struggling with rising obesity rates.
According to investment bank Jefferies, this could represent a significant opportunity for India's pharmaceutical sector, predicting that the domestic semaglutide market could expand to $1 billion if the pricing strategy and adoption rates align favorably. Analysts expect around 50 generics to enter the market quickly, mirroring previous instances where similar medicines saw an influx of alternatives once the original patents lapsed.
The Indian pharmaceutical industry, valued around $60 billion and primarily driven by generics, is set to swell massively, with semaglutide expected to become widely available at lower prices, currently ranging from 8,800 to 16,000 rupees per month. The expected change could bring the cost down to 3,000 to 5,000 rupees.
Originally designed for diabetes management, these GLP-1 receptor agonists, such as semaglutide, have garnered attention for their effectiveness in weight reduction, offering patients results previously unseen in weight management therapies.
However, as hopes for a more accessible treatment rise, industry professionals express caution regarding potential misuse of the drugs. Reports indicate misuse by unqualified practitioners and the promotion of rapid weight loss packages, raising red flags about safety and drug quality as the generics flood the market.
Doctors emphasize the importance of medical supervision and proper dosage management, underscoring a balanced approach between affordability and safety. With more than 77 million Indians experiencing type-2 diabetes, the demand for effective treatment options remains critical, and the landscape is changing rapidly.
As this transformative period unfolds, it remains essential for regulatory bodies, pharmaceutical companies, and healthcare providers to navigate the complexities of introducing affordable weight-loss medications while upholding safety standards. The next few months will be critical in determining how India can balance increased access to these potentially life-changing drugs with the necessity for stringent oversight and quality control.
